APO RESEARCH · REPORT
Oxaliplatin
Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy the third stage colon cancer after resecting primary tumor completely.
Product & engineering
Understand the product.
Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy the third stage colon cancer after resecting primary tumor completely.
In this report, only the finished drug is covered, exclude API.
Selected research
Industry Research
Oxaliplatin Industry Research Report 2026
Market perspective
Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy the third stage colon cancer after resecting primary tumor completely.
In this report, only the finished drug is covered, exclude API.
Europe is the largest market with about 33% market share. Followed by Japan, accounting for about 30% revenue market share.
Read the full market overview
The key players are Sanofi-Aventis, Yakult honsha, Dr Reddy's laboratories, Sun Pharmaceutical, Teva, Fresenius Kabi, Hospira, Mylan, Jiangsu Hengrui Medicine, Nanjing Pharmaceutical Factory, Jiangsu Aosaikang Pharmaceutical, Qilu Pharmaceutical, Hisun Pharmaceutical, Lunan Pharmaceutical, Luoxin, Halfsky Pharmacy, YRPG, Hainan Jinrui Pharmaceutical, Jari Pharmaceutical, Chiatai Tianqing etc. Top 3 companies occupied about 66% revenue market share.
Report Scope
This report quantifies the global Oxaliplatin market in terms of revenue (US$ million) and, where applicable, service volume (MT), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/MT) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oxaliplatin.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oxaliplatin Market by Company
Sanofi-Aventis
Yakult honsha
Dr Reddy's laboratories
Sun Pharmaceutical
Teva
Fresenius Kabi
Hospira
Mylan
Jiangsu Hengrui Medicine
Nanjing Pharmaceutical Factory
Jiangsu Aosaikang Pharmaceutical
Qilu Pharmaceutical
Hisun Pharmaceutical
Lunan Pharmaceutical
Luoxin
Halfsky Pharmacy
YRPG
Hainan Jinrui Pharmaceutical
Jari Pharmaceutical
Chiatai Tianqing
Oxaliplatin Segment by Type
Mannitol
Glucose Solution
Lactose Solution
Others
Oxaliplatin Segment by Application
Colorectal Cancer
Stomach Cancer
Ovarian Cancer
Others
Oxaliplatin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oxaliplatin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oxaliplatin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oxaliplatin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oxaliplatin companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Mannitol
- Glucose Solution
- Lactose Solution
- Others
Applications
- Colorectal Cancer
- Stomach Cancer
- Ovarian Cancer
- Others
Companies covered
- Sanofi-Aventis
- Yakult honsha
- Dr Reddy's laboratories
- Sun Pharmaceutical
- Teva
- Fresenius Kabi
- Hospira
- Mylan
- Jiangsu Hengrui Medicine
- Nanjing Pharmaceutical Factory
- Jiangsu Aosaikang Pharmaceutical
- Qilu Pharmaceutical
- Hisun Pharmaceutical
- Lunan Pharmaceutical
- Luoxin
- Halfsky Pharmacy
- YRPG
- Hainan Jinrui Pharmaceutical
- Jari Pharmaceutical
- Chiatai Tianqing
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oxaliplatin by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Mannitol
- 2.2.3 Glucose Solution
- 2.2.4 Lactose Solution
- 2.2.5 Others
- 2.3 Oxaliplatin by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Colorectal Cancer
- 2.3.3 Stomach Cancer
- 2.3.4 Ovarian Cancer
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Oxaliplatin Breakdown Data by Type
- 3.1 Global Oxaliplatin Historic Market Size by Type (2021-2026)
- 3.2 Global Oxaliplatin Forecasted Market Size by Type (2027-2032)
4 Oxaliplatin Breakdown Data by Application
- 4.1 Global Oxaliplatin Historic Market Size by Application (2021-2026)
- 4.2 Global Oxaliplatin Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oxaliplatin Market Perspective (2021-2032)
- 5.2 Global Oxaliplatin Growth Trends by Region
- 5.2.1 Global Oxaliplatin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oxaliplatin Historic Market Size by Region (2021-2026)
- 5.2.3 Oxaliplatin Forecasted Market Size by Region (2027-2032)
- 5.3 Oxaliplatin Market Dynamics
- 5.3.1 Oxaliplatin Industry Trends
- 5.3.2 Oxaliplatin Market Drivers
- 5.3.3 Oxaliplatin Market Challenges
- 5.3.4 Oxaliplatin Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oxaliplatin Players by Revenue
- 6.1.1 Global Top Oxaliplatin Players by Revenue (2021-2026)
- 6.1.2 Global Oxaliplatin Revenue Market Share by Players (2021-2026)
- 6.2 Global Oxaliplatin Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oxaliplatin Head Office and Area Served
- 6.4 Global Oxaliplatin Players, Product Type & Application
- 6.5 Global Oxaliplatin Manufacturers Established Date
- 6.6 Global Oxaliplatin Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oxaliplatin Market Size (2021-2032)
- 7.2 North America Oxaliplatin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oxaliplatin Market Size by Country (2021-2026)
- 7.4 North America Oxaliplatin Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oxaliplatin Market Size (2021-2032)
- 8.2 Europe Oxaliplatin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oxaliplatin Market Size by Country (2021-2026)
- 8.4 Europe Oxaliplatin Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oxaliplatin Market Size (2021-2032)
- 9.2 Asia-Pacific Oxaliplatin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oxaliplatin Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oxaliplatin Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oxaliplatin Market Size (2021-2032)
- 10.2 South America Oxaliplatin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oxaliplatin Market Size by Country (2021-2026)
- 10.4 South America Oxaliplatin Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oxaliplatin Market Size (2021-2032)
- 11.2 Middle East & Africa Oxaliplatin Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oxaliplatin Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oxaliplatin Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi-Aventis
- 12.1.1 Sanofi-Aventis Company Information
- 12.1.2 Sanofi-Aventis Business Overview
- 12.1.3 Sanofi-Aventis Revenue in Oxaliplatin Business (2021-2026)
- 12.1.4 Sanofi-Aventis Oxaliplatin Product Portfolio
- 12.1.5 Sanofi-Aventis Recent Developments
- 12.2 Yakult honsha
- 12.2.1 Yakult honsha Company Information
- 12.2.2 Yakult honsha Business Overview
- 12.2.3 Yakult honsha Revenue in Oxaliplatin Business (2021-2026)
- 12.2.4 Yakult honsha Oxaliplatin Product Portfolio
- 12.2.5 Yakult honsha Recent Developments
- 12.3 Dr Reddy's laboratories
- 12.3.1 Dr Reddy's laboratories Company Information
- 12.3.2 Dr Reddy's laboratories Business Overview
- 12.3.3 Dr Reddy's laboratories Revenue in Oxaliplatin Business (2021-2026)
- 12.3.4 Dr Reddy's laboratories Oxaliplatin Product Portfolio
- 12.3.5 Dr Reddy's laboratories Recent Developments
- 12.4 Sun Pharmaceutical
- 12.4.1 Sun Pharmaceutical Company Information
- 12.4.2 Sun Pharmaceutical Business Overview
- 12.4.3 Sun Pharmaceutical Revenue in Oxaliplatin Business (2021-2026)
- 12.4.4 Sun Pharmaceutical Oxaliplatin Product Portfolio
- 12.4.5 Sun Pharmaceutical Recent Developments
- 12.5 Teva
- 12.5.1 Teva Company Information
- 12.5.2 Teva Business Overview
- 12.5.3 Teva Revenue in Oxaliplatin Business (2021-2026)
- 12.5.4 Teva Oxaliplatin Product Portfolio
- 12.5.5 Teva Recent Developments
- 12.6 Fresenius Kabi
- 12.6.1 Fresenius Kabi Company Information
- 12.6.2 Fresenius Kabi Business Overview
- 12.6.3 Fresenius Kabi Revenue in Oxaliplatin Business (2021-2026)
- 12.6.4 Fresenius Kabi Oxaliplatin Product Portfolio
- 12.6.5 Fresenius Kabi Recent Developments
- 12.7 Hospira
- 12.7.1 Hospira Company Information
- 12.7.2 Hospira Business Overview
- 12.7.3 Hospira Revenue in Oxaliplatin Business (2021-2026)
- 12.7.4 Hospira Oxaliplatin Product Portfolio
- 12.7.5 Hospira Recent Developments
- 12.8 Mylan
- 12.8.1 Mylan Company Information
- 12.8.2 Mylan Business Overview
- 12.8.3 Mylan Revenue in Oxaliplatin Business (2021-2026)
- 12.8.4 Mylan Oxaliplatin Product Portfolio
- 12.8.5 Mylan Recent Developments
- 12.9 Jiangsu Hengrui Medicine
- 12.9.1 Jiangsu Hengrui Medicine Company Information
- 12.9.2 Jiangsu Hengrui Medicine Business Overview
- 12.9.3 Jiangsu Hengrui Medicine Revenue in Oxaliplatin Business (2021-2026)
- 12.9.4 Jiangsu Hengrui Medicine Oxaliplatin Product Portfolio
- 12.9.5 Jiangsu Hengrui Medicine Recent Developments
- 12.10 Nanjing Pharmaceutical Factory
- 12.10.1 Nanjing Pharmaceutical Factory Company Information
- 12.10.2 Nanjing Pharmaceutical Factory Business Overview
- 12.10.3 Nanjing Pharmaceutical Factory Revenue in Oxaliplatin Business (2021-2026)
- 12.10.4 Nanjing Pharmaceutical Factory Oxaliplatin Product Portfolio
- 12.10.5 Nanjing Pharmaceutical Factory Recent Developments
- 12.11 Jiangsu Aosaikang Pharmaceutical
- 12.11.1 Jiangsu Aosaikang Pharmaceutical Company Information
- 12.11.2 Jiangsu Aosaikang Pharmaceutical Business Overview
- 12.11.3 Jiangsu Aosaikang Pharmaceutical Revenue in Oxaliplatin Business (2021-2026)
- 12.11.4 Jiangsu Aosaikang Pharmaceutical Oxaliplatin Product Portfolio
- 12.11.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
- 12.12 Qilu Pharmaceutical
- 12.12.1 Qilu Pharmaceutical Company Information
- 12.12.2 Qilu Pharmaceutical Business Overview
- 12.12.3 Qilu Pharmaceutical Revenue in Oxaliplatin Business (2021-2026)
- 12.12.4 Qilu Pharmaceutical Oxaliplatin Product Portfolio
- 12.12.5 Qilu Pharmaceutical Recent Developments
- 12.13 Hisun Pharmaceutical
- 12.13.1 Hisun Pharmaceutical Company Information
- 12.13.2 Hisun Pharmaceutical Business Overview
- 12.13.3 Hisun Pharmaceutical Revenue in Oxaliplatin Business (2021-2026)
- 12.13.4 Hisun Pharmaceutical Oxaliplatin Product Portfolio
- 12.13.5 Hisun Pharmaceutical Recent Developments
- 12.14 Lunan Pharmaceutical
- 12.14.1 Lunan Pharmaceutical Company Information
- 12.14.2 Lunan Pharmaceutical Business Overview
- 12.14.3 Lunan Pharmaceutical Revenue in Oxaliplatin Business (2021-2026)
- 12.14.4 Lunan Pharmaceutical Oxaliplatin Product Portfolio
- 12.14.5 Lunan Pharmaceutical Recent Developments
- 12.15 Luoxin
- 12.15.1 Luoxin Company Information
- 12.15.2 Luoxin Business Overview
- 12.15.3 Luoxin Revenue in Oxaliplatin Business (2021-2026)
- 12.15.4 Luoxin Oxaliplatin Product Portfolio
- 12.15.5 Luoxin Recent Developments
- 12.16 Halfsky Pharmacy
- 12.16.1 Halfsky Pharmacy Company Information
- 12.16.2 Halfsky Pharmacy Business Overview
- 12.16.3 Halfsky Pharmacy Revenue in Oxaliplatin Business (2021-2026)
- 12.16.4 Halfsky Pharmacy Oxaliplatin Product Portfolio
- 12.16.5 Halfsky Pharmacy Recent Developments
- 12.17 YRPG
- 12.17.1 YRPG Company Information
- 12.17.2 YRPG Business Overview
- 12.17.3 YRPG Revenue in Oxaliplatin Business (2021-2026)
- 12.17.4 YRPG Oxaliplatin Product Portfolio
- 12.17.5 YRPG Recent Developments
- 12.18 Hainan Jinrui Pharmaceutical
- 12.18.1 Hainan Jinrui Pharmaceutical Company Information
- 12.18.2 Hainan Jinrui Pharmaceutical Business Overview
- 12.18.3 Hainan Jinrui Pharmaceutical Revenue in Oxaliplatin Business (2021-2026)
- 12.18.4 Hainan Jinrui Pharmaceutical Oxaliplatin Product Portfolio
- 12.18.5 Hainan Jinrui Pharmaceutical Recent Developments
- 12.19 Jari Pharmaceutical
- 12.19.1 Jari Pharmaceutical Company Information
- 12.19.2 Jari Pharmaceutical Business Overview
- 12.19.3 Jari Pharmaceutical Revenue in Oxaliplatin Business (2021-2026)
- 12.19.4 Jari Pharmaceutical Oxaliplatin Product Portfolio
- 12.19.5 Jari Pharmaceutical Recent Developments
- 12.20 Chiatai Tianqing
- 12.20.1 Chiatai Tianqing Company Information
- 12.20.2 Chiatai Tianqing Business Overview
- 12.20.3 Chiatai Tianqing Revenue in Oxaliplatin Business (2021-2026)
- 12.20.4 Chiatai Tianqing Oxaliplatin Product Portfolio
- 12.20.5 Chiatai Tianqing Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst